SHPG:NGS-Shire plc

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 177.36

Change

+1.85 (+1.05)%

Market Cap

USD 54.08B

Volume

0.83M

Average Target Price

USD 197.83 (11.54%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Shire PLC is a biotech company. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-10-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

+0.43 (+0.21%)

USD 131.25B
GILD Gilead Sciences Inc.

-0.69 (-0.90%)

USD 98.03B
BIIB Biogen Inc.

-0.38 (-0.11%)

USD 68.13B
CELG Celgene Corporation

N/A

USD 59.28B
VRTX Vertex Pharmaceuticals Incorpo..

+0.03 (+0.02%)

USD 47.40B
REGN Regeneron Pharmaceuticals Inc.

+0.54 (+0.14%)

USD 43.12B
ALXN Alexion Pharmaceuticals Inc.

+1.24 (+0.97%)

USD 28.74B
BMRN BioMarin Pharmaceutical Inc.

+0.06 (+0.06%)

USD 18.84B
INCY Incyte Corporation

+0.13 (+0.20%)

USD 13.83B
GRFS Grifols S.A.

-0.04 (-0.20%)

USD 13.49B

ETFs Containing SHPG

BBH VanEck Vectors Biotech ET.. 5.05 % 0.35 %

+0.17 (+0.14%)

USD 0.45B
EUR:CA First Trust AlphaDEX Euro.. 4.60 % 0.67 %

+0.06 (+0.26%)

CAD 0.02B
EUR.A:CA First Trust AlphaDEX Euro.. 4.60 % 1.77 %

N/A

CAD 1.77M
FPX First Trust US Equity Opp.. 4.22 % 0.59 %

-0.22 (-0.31%)

USD 1.14B
PBI.B:CA Purpose Best Ideas Fund 4.03 % 0.91 %

N/A

CAD 5.19M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.34% 69% D+ 75% C
Dividend Return 0.68% 14% F 17% F
Total Return 15.02% 69% D+ 75% C
Trailing 12 Months  
Capital Gain 16.65% 71% C- 74% C
Dividend Return 0.70% 14% F 12% F
Total Return 17.34% 71% C- 74% C
Trailing 5 Years  
Capital Gain 45.37% 71% C- 59% F
Dividend Return 3.37% 27% F 12% F
Total Return 48.73% 71% C- 57% F
Average Annual (5 Year Horizon)  
Capital Gain 0.09% 43% F 33% F
Dividend Return 0.53% 43% F 30% F
Total Return 0.44% 19% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 26.74% 79% C+ 49% F
Risk Adjusted Return 2.00% 43% F 28% F
Market Capitalization 51.98B 99% A+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.13 7% F 43% F
Price/Book Ratio 1.44 75% C 65% D
Price / Cash Flow Ratio 2.98 8% F 38% F
Price/Free Cash Flow Ratio 14.33 6% F 33% F
Management Effectiveness  
Return on Equity 13.49% 85% B 76% C
Return on Invested Capital 8.23% 86% B 65% D
Return on Assets 7.16% 94% A 83% B
Debt to Equity Ratio 42.75% 32% F 51% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

SHPG:NGS-Shire plc

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 177.36

Change

+1.85 (+1.05)%

Market Cap

USD 54.08B

Volume

0.83M

Average Target Price

USD 197.83 (11.54%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-10-17